advertisement

WGA Rescources

Guo L 15

Showing records 1 to 15 | Display all abstracts from Guo L

106737 MicroRNA-210-3p mediates trabecular meshwork extracellular matrix accumulation and ocular hypertension - Implication for novel glaucoma therapy
Zhao S
Experimental Eye Research 2023; 227: 109350
106511 Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
Li S; Guo L
Eye and vision (London, England) 2022; 9: 44
106737 MicroRNA-210-3p mediates trabecular meshwork extracellular matrix accumulation and ocular hypertension - Implication for novel glaucoma therapy
Fang L
Experimental Eye Research 2023; 227: 109350
106511 Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
Zhou P
Eye and vision (London, England) 2022; 9: 44
106737 MicroRNA-210-3p mediates trabecular meshwork extracellular matrix accumulation and ocular hypertension - Implication for novel glaucoma therapy
Yan C
Experimental Eye Research 2023; 227: 109350
106511 Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
Tang J
Eye and vision (London, England) 2022; 9: 44
106737 MicroRNA-210-3p mediates trabecular meshwork extracellular matrix accumulation and ocular hypertension - Implication for novel glaucoma therapy
Wei J; Song D
Experimental Eye Research 2023; 227: 109350
106511 Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
Wang Z
Eye and vision (London, England) 2022; 9: 44
106737 MicroRNA-210-3p mediates trabecular meshwork extracellular matrix accumulation and ocular hypertension - Implication for novel glaucoma therapy
Xu C
Experimental Eye Research 2023; 227: 109350
106511 Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
Zhang L
Eye and vision (London, England) 2022; 9: 44
106737 MicroRNA-210-3p mediates trabecular meshwork extracellular matrix accumulation and ocular hypertension - Implication for novel glaucoma therapy
Luo Y
Experimental Eye Research 2023; 227: 109350
106511 Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
Zhao M
Eye and vision (London, England) 2022; 9: 44
106737 MicroRNA-210-3p mediates trabecular meshwork extracellular matrix accumulation and ocular hypertension - Implication for novel glaucoma therapy
Fan Y
Experimental Eye Research 2023; 227: 109350
106511 Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
Qu J
Eye and vision (London, England) 2022; 9: 44
106737 MicroRNA-210-3p mediates trabecular meshwork extracellular matrix accumulation and ocular hypertension - Implication for novel glaucoma therapy
Guo L; Sun H; Guo T
Experimental Eye Research 2023; 227: 109350

Issue 23-3

Change Issue


advertisement

Bioniko